Genomics: Drugs, diabetes and cancer

Nature. 2011 Feb 17;470(7334):338-9. doi: 10.1038/470338a.

Abstract

Variation in a genomic region that contains the cancer-a ssociated gene ATM affects a patient’s response to the diabetes drug metformin. Two experts discuss the implications for understanding diabetes and the link to cancer.

Publication types

  • News

MeSH terms

  • Adenylate Kinase / metabolism
  • Animals
  • Ataxia Telangiectasia Mutated Proteins
  • Blood Glucose / analysis
  • Blood Glucose / biosynthesis
  • Cell Cycle Proteins / antagonists & inhibitors
  • Cell Cycle Proteins / genetics*
  • Cell Cycle Proteins / metabolism*
  • DNA-Binding Proteins / antagonists & inhibitors
  • DNA-Binding Proteins / genetics*
  • DNA-Binding Proteins / metabolism*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / genetics*
  • Energy Intake
  • Enzyme Activation / drug effects
  • Female
  • Genome-Wide Association Study
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Metformin / pharmacology*
  • Neoplasms / drug therapy
  • Neoplasms / genetics*
  • Neoplasms / pathology
  • Pharmacogenetics
  • Polycystic Ovary Syndrome / complications
  • Protein-Serine-Threonine Kinases / antagonists & inhibitors
  • Protein-Serine-Threonine Kinases / genetics*
  • Protein-Serine-Threonine Kinases / metabolism*
  • Tumor Suppressor Proteins / antagonists & inhibitors
  • Tumor Suppressor Proteins / genetics*
  • Tumor Suppressor Proteins / metabolism*

Substances

  • Blood Glucose
  • Cell Cycle Proteins
  • DNA-Binding Proteins
  • Hypoglycemic Agents
  • Tumor Suppressor Proteins
  • Metformin
  • STK11 protein, human
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • Protein-Serine-Threonine Kinases
  • Adenylate Kinase